
埃博拉病毒已为人所知数十年,但针对导致当前疫情的邦迪布焦毒株,仍无可用疫苗。最新研究让人们对预防各类埃博拉病毒燃起希望。
Ebola has been known about for decades, but there is still no vaccine against the Bundibugyo strain of the virus causing the current outbreak. New research raises hopes of protection against the various types of Ebola.
谷歌搜索首选德国之声 研究人员正致力于开发针对当前疫情致病毒株的疫苗 1976年:一种此前未知的疾病在当时称为扎伊尔、现为刚果民主共和国(DRC)的埃博拉河附近爆发。这是首次有科学记录的埃博拉疫情。
Prefer DW on Google Researchers are working to develop a vaccine against the strain of Ebola responsible for the current outbreak 1976: A hitherto unknown disease breaks out near the Ebola river in the country then known as Zaire, now the Democratic Republic of Congo (DRC). This was the first scientifically documented Ebola epidemic.
如今,50年过去,刚果民主共和国再次成为一场大规模埃博拉疫情的中心。此次病原体是正埃博拉病毒属中较罕见的邦迪布焦型。该病毒于2007年在乌干达邦迪布焦爆发时被确认,2012年刚果民主共和国曾再度发生疫情。
Now, 50 years on, the DRC once again finds itself at the center of a major Ebola outbreak This time the pathogen is the less common Bundibugyo type of the genus Orthoebolavirus. The virus was identified in 2007 during an outbreak in Bundibugyo, Uganda Another outbreak occurred in the DRC in 2012.
邦迪布焦:本可提前做好准备 一种已为人所知数十年的病毒,为何仍持续感染数千人,却至今没有获批疫苗或官方治疗方案?
Bundibugyo: Preparations could have been made How can a virus that has been known for decades continue to infect thousands of people, yet there is still no licensed vaccine or official treatment?
杜塞尔多夫大学医院热带医学博士托尔斯滕·费尔特认为,这是一次错失的良机。“我们在之前两次疫情中已接触过邦迪布焦病毒:2007年和2012年在刚果民主共和国。因此我们有足够时间开发疫苗和治疗方案。但我们未利用这一机会,导致当前疫情中损失了宝贵时间。”德国感染研究中心(DZIF)及汉堡-埃彭多夫大学医学中心感染研究与疫苗开发研究所的莱奥妮·迈耶持相同看法。
Torsten Feldt, a doctor of tropical medicine at Düsseldorf's University Hospital, sees this as a missed opportunity. "We had come across the Bundibugyo virus in two previous outbreaks: 2007 in and 2012 in DR Congo. So we had enough time to develop vaccines and therapeutic options. But we didn't make use of this opportunity, meaning crucial time was lost during the current outbreak." Leonie Mayer from the German Center for Infection Research (DZIF) and the Institute for Infection Research and Vaccine Development at the University Medical Center in Hamburg-Eppendorf agrees.
“他们当然本可以更早开发疫苗并开展临床前试验,”迈耶对德国之声表示。但她强调,疫苗的有效性只能在实际疫情中得到评估和确认。
"They could of course have developed a vaccine and run pre-clinical trials before," Mayer told DW. She stressed, however, that their effectiveness can only be assessed and confirmed during an actual outbreak.
Mayer 是一项最新发表研究的第一作者,该研究考察了已获许可的埃博拉疫苗 Ervebo 能否用于预防其他类型的埃博拉病毒。
Mayer is the lead author of a recently published study that examined whether Ervebo, an Ebola vaccine that has already been licensed, can be used against other types of Ebola as well.
刚果(金)埃博拉危机:恐惧、不信任与不断扩大的疫情 观看此视频 ,以及 为什么埃博拉是疫苗研发的良好候选者 从免疫学角度来看,与流感病毒或人类免疫缺陷病毒相比,埃博拉是非常值得研发疫苗的候选者。
Congo's Ebola crisis: Fear, mistrust and a growing outbreak To view this video , and Why Ebola is a good candidate for vaccine development From an immunological point of view, and compared to — for example — influenza or Ebola is a very worthwhile candidate for a vaccine.
流感病毒不断变异,而人类免疫缺陷病毒特别善于逃避我们的免疫防御。埃博拉则可预测得多。
Influenza viruses are constantly mutating, and the human immunodeficiency virus is particularly good at evading our immune defenses. Ebola is far more predictable.
“我认为——这或许算是因祸得福——研发针对邦迪布焦病毒的疫苗将相对简单直接,”Mayer 说。
"I think — and perhaps it's kind of a blessing in disguise — that it will be relatively straightforward to develop a vaccine against Bundibugyo," says Mayer.
这里存在一个悖论。从科学角度看,埃博拉是良好的疫苗候选者,但针对目前正在传播的邦迪布焦变体,仍无获许可的预防手段。
Herein lies the paradox. From a scientific point of view, Ebola is a good vaccine candidate, yet there is still no licensed form of prevention against the Bundibugyo variant that is currently circulating.
Mayer 解释说,疫苗不能作为预防措施针对每一种潜在病原体进行开发。缺乏资金或优先研发其他病原体往往起着作用。许多研究人员曾认为苏丹埃博拉病毒再次爆发的可能性更大,因此针对该毒株的疫苗研发更为先进。
Mayer explains that vaccines cannot be developed as a precautionary measure against every potential pathogen. Lack of funding or the prioritization of other pathogens often have a role to play. Many researchers had assumed that a fresh outbreak of the Sudan Ebola virus was more likely, and vaccine development for this strain is more advanced.
不同类型的埃博拉 问题的另一部分在于,埃博拉并非单一病毒。已知的高危正埃博拉病毒包括埃博拉病毒(EBOV),此前称为扎伊尔埃博拉病毒(ZEBOV)、苏丹病毒(SUDV)和邦迪布焦病毒(BDBV)。现有疫苗 Ervebo 是针对扎伊尔变体开发并获许可使用的。但针对其他类型,仍无获批的防护手段。这就是为什么现有埃博拉疫苗对当前疫情地区的人们作用有限。
Different types of Ebola Another part of the problem is that Ebola is not one single virus. The known, highly dangerous orthoebolaviruses include Ebola virus (EBOV), previously called the Zaire Ebola virus (ZEBOV), the Sudan virus (SUDV), and the Bundibugyo virus (BDBV). The existing vaccine, Ervebo, was developed and licensed for use against the Zaire variant. But there is still no approved protection against the others. This is why the existing Ebola vaccine has been of only limited use to people in the areas of the current outbreak.
另一个可能相关的因素是:邦迪布焦病毒似乎比扎伊尔变种毒性较弱。乍听之下这像是个好消息,但可能会让疫情更难控制,因为感染者在发病后能保持活动能力的时间更长,可能在不知情的情况下传播病毒。Ervebo疫苗:对邦迪布焦病毒的免疫反应在最近发表的一项研究中,来自德国感染研究中心(DZIF)的迈耶研究团队调查了已获批的埃博拉疫苗是否不仅能针对埃博拉病毒(EBOV),还能针对其他类型的埃博拉病毒触发免疫反应。
Another factor may also be relevant: The Bundibugyo virus appears to be less aggressive than the Zaire variant. At first, that sounds like good news, but it may make it harder to contain, as people remain mobile for longer after being infected, and can pass on the virus without realizing Ervebo vaccine: Immune response to Bundibugyo In the recently published study, Mayer's research team from the DZIF investigated whether the already licensed Ebola vaccine could trigger an immune response not only against EBOV, but against other types of Ebola as well.
他们发现了针对邦迪布焦病毒的交叉反应性T细胞反应,以及在较小程度上针对苏丹病毒的反应。
They found cross-reactive T-cell responses against Bundibugyo, and also, to a lesser extent, against the Sudan virus.
对迈耶而言,这已是一个重要发现:“我们现在知道,免疫细胞极有可能也能识别邦迪布焦病毒。”但她同时指出:“我们的数据无法回答这种免疫反应是否真能提供保护,或者是否会导致病情进展变轻。”这目前是一个重要的知识空白。为何现有疫苗目前无法投入使用既然已有一款获批疫苗,且有迹象表明它可能保护人们,为何不直接投入使用?
For Mayer, this is already an important finding: "We now know that the immune cells can most likely also recognize the Bundibugyo virus." But she also observes: "Our data does not enable us to answer the question of whether this immune response actually provides protection, or if it results in a milder progression of the disease." This is currently an important gap in our knowledge. Why the existing vaccine cannot currently be deployed If there's a vaccine that has already been licensed, and indications that it could protect people, why isn't it simply being deployed?
迈耶解释了这一困境。首先,她说,如果不确定疫苗是否有效或效果如何,投入使用在伦理上是不允许的。此外,如果大规模使用,将无法再确定它是否真正有效:病例减少也可能是其他措施的结果,或者疫情可能已过高峰。
Mayer explains the dilemma. For one thing, she says, it's not ethical to deploy a vaccine if you're not sure whether or how well it works. Also, if it were used on a large scale, it would no longer be possible to establish whether it actually works: A reduction in cases could also be a result of other measures, or the epidemic might already have passed its peak.
伯恩哈德·诺赫特研究所热带病专家于尔根·梅也对大规模接种发出警告:“在缺乏功效证据的情况下进行大规模接种,可能会造成虚假的安全感,丧失信任,并且如果保护力不足,会使研究变得不可能。” 现场的接受度非常重要。“如果我们大规模给人们接种一种疫苗,事后却发现它远不如我们预期的那样有效,要向现场民众传达这一点非常困难,”梅耶说。在最坏的情况下,人们随后可能会拒绝接种更有效的疫苗。
Jürgen May, a specialist in tropical diseases at the Bernhard Nocht Institute, also warns against mass vaccination: "Mass vaccination without proof of efficacy could create a false sense of security, forfeit trust, and, if it does not provide sufficient protection, make study impossible." It's very important for there to be acceptance on the ground. "If we inoculate people with a vaccine on a large scale, and afterwards it turns out that it was nothing like as effective as we expected, it's very difficult to communicate that to people on the ground," Mayer says. In a worst-case scenario, people could subsequently refuse inoculation with more effective vaccines.
埃博拉为何依然难以遏制 但目前的疫情也表明,仅靠医疗创新是不够的。
Why Ebola is still so difficult to contain But the current outbreak also shows that medical innovation alone is not enough.
冲突、艰难的交通路线、对医疗设施的袭击以及接触者追踪的漏洞,都增加了遏制疫情的难度。
Conflicts difficult transport routes, attacks on healthcare facilities, and gaps in contact tracing all make it harder to contain.
自5月以来,刚果(金)已出现超过1万例邦迪布焦病例。最近,肯尼亚和尼日利亚也报告了病例。托尔斯滕·费尔特表示,识别邦迪布焦病毒本身不再是问题。限制因素往往在于诊断工具的实际可获得性。“在偏远或受冲突影响的地区,样本往往需要长途运输,”他解释道。
The DRC has had more than 10,000 cases of Bundibugyo since May. Recently, it has also been reported in Kenya and Nigeria Torsten Feldt says identifying Bundibugyo is no longer a problem in itself. What is often limiting is the practical availability of diagnostic tools. "In remote or conflict-affected regions, samples often have to be transported over long distances," he explains.
这里我们看到了另一个埃博拉悖论。世界在诊断感染方面越来越强,但仍难以足够快地遏制疫情爆发。《自然》杂志当期一篇文章的作者得出了相同结论:问题往往不在于识别病例,而在于人们反应的速度。他们写道:“发现埃博拉现在往往比阻止埃博拉更容易。”从邦迪布焦疫苗到全埃博拉疫苗?
Here we see another Ebola paradox. The world is getting ever better at diagnosing infections, but it still struggles to contain outbreaks fast enough. The authors of an article in the current issue of Nature come to the same conclusion: The problem is often not identifying cases, but the speed with which people react. Finding Ebola is often easier now than stopping Ebola they write. From a Bundibugyo vaccine to a pan-Ebola one?
许多研究人员认为,当前的危机也可能提供一个巨大的机遇。所谓的“图迈尼研究”已在刚果(金)启动,正在测试不同的疫苗候选物。
Many researchers believe the current crisis could potentially also provide a great opportunity. The so-called Tumaini study, which is testing different vaccine candidates, has now been launched in the DRC.
这些疫苗包括由牛津大学开发的 Ervebo 以及一款 Moderna mRNA 疫苗。该研究旨在提供关于这些疫苗对班迪布焦病毒功效的首批可靠数据。
These include Ervebo, developed by Oxford University, and a Moderna mRNA vaccine The study aims to provide the first reliable data about their efficacy against the Bundibugyo virus.
这些疫苗是否仍有助于控制当前疫情尚不确定。虽然存有希望,但专家估计,实际上要等到几个月后,任何此类疫苗才能广泛使用;或许要等到 2027 年年中。
Whether these vaccines could still help control the current outbreak is uncertain. There is hope, but experts estimate that, realistically, it will be several months before any such vaccine is available for widespread use; perhaps not until mid-2027.
“理想情况下,我们将开发出交叉反应的全埃博拉病毒疫苗,”DZIF 研究的合著者 Christof Geldmacher 谈到他们的长期计划时表示。这方面工作也在进行中。但目前,重点是开发针对该病毒班迪布焦变种的有效疫苗。本文译自德语。
"Ideally, we will develop cross-reactive pan-Ebola vaccines," Christof Geldmacher, a co-author of the DZIF study, says of their long-term plans. This is also something that is being worked on. For now, though, the focus is on developing an effective vaccine against the Bundibugyo variant of the virus. This article has been translated from German.